Lindahl advises Senzime AB on directed share issue

The issue is covered in its entirety by binding application forms and subscription undertakings. Through the issue, which is carried out in two separate tranches, Senzime will receive approximately SEK 86 million before deduction of issue costs. Senzime intends to use the net proceeds from the share issue to continue the commercial expansion, ensure the progress of ongoing innovation projects and finance the company's working capital needs in line with the expected growth. Furthermore, the share issue means that the company strengthens the shareholder base with additional long-term, strategically important and international investors.

Senzime is a Swedish medical technology company that develops and markets CE- and FDA-approved patient monitoring systems. The company's shares are listed on Nasdaq Stockholm Main Market.

Lindahl's team consists of Mattias Prage, Andreas Mellberg, Michaela Larsson and Olle Swärd Brattström.